Enhanced Provides Clinician-Led Access to Six New Peptides

Enhanced Group (ENHA) has begun offering eligible consumers prescription-only access to six additional peptides through its Live Enhanced telehealth platform.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Prescription-only access through licensed clinicians and U.S. licensed pharmacies begins today

Quality-tested ingredients, trained prescribing clinicians and defined clinical protocols

NEW YORK--(BUSINESS WIRE)-- Enhanced Group Inc. (NYSE: ENHA) (“Enhanced” or the “Company”) today announced that, beginning today, it provides eligible consumers safe and medically supervised access to six peptides through licensed clinicians on the Live Enhanced telehealth platform, following the policy announced by the U.S. Department of Health and Human Services (HHS) on October 28, 2026.

Enhanced’s existing peptide offering of GHK-Cu and Sermorelin is now complemented by BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax.

All six peptides are available by prescription only, after an individual evaluation by a licensed clinician.

For more information on the product offering, visit enhanced.com.

Built on Quality and Clinical Standards

Enhanced’s peptide offering is designed around the following standards:

• Prescription only. Every peptide is prescribed by a licensed clinician after reviewing the individual’s health history and goals. If a peptide is not appropriate, it is not prescribed.
• Trained clinicians, defined protocols. Prescribing clinicians have completed training on these peptides and follow Enhanced’s clinical protocols developed with Enhanced’s medical commission.
• Compounded in the United States. Each peptide is compounded and dispensed by a state-licensed U.S. pharmacy, in the forms and routes the policy permits, one peptide per preparation.
• Quality-controlled ingredients. Active pharmaceutical ingredients come from FDA-registered, CGMP-compliant manufacturers and are accompanied by certificates of analysis, with identity, purity and quality testing.
• Ongoing oversight. Clinicians remain involved throughout treatment, and Enhanced monitors outcomes and safety under clinician supervision.

“This is a significant step for Live Enhanced and for Enhanced as a company. Our customers have been asking for clinician-led access to these peptides, and we now have the clinical protocols, pharmacy partners and platform to offer it responsibly. It deepens what Live Enhanced offers every member, and it positions us well as the regulatory picture develops. We believe the right way to grow in this category is with medical supervision by licensed clinicians, regulated pharmacies and quality-controlled ingredients,” said Maximilian Martin, Co-Founder and Chief Executive Officer of Enhanced.

Enhanced intends to refine its protocols with its clinical partners and adjust as the evidence and regulatory landscape develop. FDA rulemaking on the 503A bulk drug substances list is ongoing, and the advisory committee is expected to review additional peptides in February 2027. Enhanced may expand access if and as regulators act.

About Enhanced Group, Inc.

Enhanced (NYSE: ENHA) is an elite sports competition and performance products company committed to giving athletes and consumers access to products that optimize health, performance, and recovery. Its Live Enhanced platform provides consumers with clinician-guided protocols, supplements, and personalized health and longevity offerings. For more information, visit www.enhanced.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's plans and expectations with respect to the availability and offering of peptides through the Live Enhanced platform; the Company's relationships with independent licensed clinicians and pharmacies; the anticipated role of clinician oversight in the evaluation, prescription and monitoring of patients; the Company's plans to maintain and develop clinical protocols and refine protocols with its clinical partners and respond to developments in the scientific evidence and regulatory landscape; and the potential expansion of the Company's offerings as applicable laws permit. These statements are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. For a discussion of these and other risks and uncertainties, see the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and the Company’s other filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261103728199/en/

Investor Contact
investors@enhanced.com

Media Contact
media@enhanced.com

Source: Enhanced Group Inc.

Key Terms

active pharmaceutical ingredients medical

The active pharmaceutical ingredient (API) is the specific chemical or biological substance in a medicine that produces the intended health effect — the ‘engine’ that treats, prevents or diagnoses a condition. Investors watch APIs because they determine a drug’s cost, quality, regulatory approval and patent protection; shortages, manufacturing problems or competition at the API level can directly affect a drug maker’s sales and valuation.

cgmp-compliant regulatory

cGMP-compliant means a manufacturer follows the current Good Manufacturing Practices required by regulators to ensure products are made safely, consistently and with documented quality controls. For investors, cGMP compliance is like a certified clean kitchen and recipe book for a company’s manufacturing: it reduces the risk of product contamination, regulatory sanctions or recalls, supports reliable supply and can be essential for getting and keeping market approvals.

503a bulk drug substances list regulatory

A regulatory list tied to section 503A of the U.S. Food, Drug, and Cosmetic Act that identifies bulk active pharmaceutical ingredients traditional compounding pharmacies are allowed to use when making patient-specific compounded medications without each drug having full FDA approval. It matters to investors because inclusion or exclusion affects a pharmacy’s legal ability to compound and a supplier’s market opportunity—like a restaurant’s menu determining what dishes it can legally prepare.